27.4.2012 1(17)

Unless otherwise stated, figures in parenthesis refer to the corresponding period in the previous

year.

- Net sales amounted to 18.9 (22.1) million euro, down 14.3%.

- Operating profit was 1.5 (2.8) million euro corresponding to 8.1% of net sales.

- Profit for the period was 0.7 (2.7) million euro.

- Basic earnings per share was 0.04 (0.16) euro.

- Net cash flow from operations amounted to -1.0 (-1.3) million euro.

The customer industries are estimated to grow moderately in Okmetic’s main product groups in

2012. The levelling of semiconductor industry’s inventories, which started in mid-2011, seems

to have ended in the end of the period under review, as anticipated. The orders of

semiconductor wafers began to increase in March. This indicates that the downward trend of

around three quarters has ended.

The development of sensor wafer demand is estimated to be somewhat more stable in 2012

than the demand for semiconductor wafers. The growth of sensor wafer demand seems to

focus on the second half of the year, while the beginning of the year is still a time of lower

demand.

Technology sales will focus on solar crystal sales, and be fairly even until the shipment

contracts that are valid until the third quarter will be terminating. The solar cell industry’s

strongly lowered price level is likely to accelerate the consolidation in the industry. This

development has no direct effects on Okmetic’s technology business.

The company retains the existing guidance, according to which the net sales and operating

profit for 2012 are estimated to exceed the level of 2011, although they remained under the

level of the comparison period in the first quarter, as anticipated.

”The semiconductor market which took a downward turn in summer 2011 hit the rock bottom

in January-February. The long-awaited turn for the better was evident in March, after which the

order backlog has started to grow. As predicted, Okmetic’s net sales and operating profit in the

first quarter remained under the strong level of the comparison period. Thanks to the sales

efforts the company's market share rose to a record level in the first quarter in the product

groups important to the company, which partly softened the impact of the steep market drop on

the company’s operation.

The operating profit of the first quarter was lowered significantly due to a disturbance that took

place in the production chain of a gas in the USA. The gas is used in the manufacture of epi-

coated wafers. In practice, Okmetic's Allen production plant had to be idled for almost a month.

The shipments of epi wafers during the shutdown were only a fraction of the order backlog, and

the first quarter in the US-based subsidiary was in this respect unprofitable.

2(17)

The delivery disturbance that burdened the entire industry in the US was caused by a fault in the

process of the only gas supplier on the market. The fault has since been located and fixed. The

company believes it can deliver majority of the lost orders during the rest of the year.

In the first quarter, the operating profit was also weakened by the less advantageous product

mix compared to the previous quarter and to the corresponding quarter last year, some non-

recurring expense items related to foreign subsidiaries, and the changes in the fair value of

electricity derivatives as the price of electricity declined further. The capacity utilisation rate was

deliberately maintained partly with products of lower margin.

Despite the several challenges, the operating profit (8.1%) in the first quarter nearly reached the

minimum level of 10 percent which is the company’s long-term objective. The factors behind the

success are the business volume that has increased in recent years and the supply chain that is

more flexible than before and continuously under development.

The clear decline in the profit for the period in relation to the comparison period was caused not

only by lower operating profit but also by a difference of nearly one million euro in income tax

entered as expenses. Along with the good profitability development in recent years, Okmetic

managed to deduct the earlier confirmed losses from its result by the end of summer 2011.

Similar to last year, the net cash flow of the period under review was weighed down by advance

payments and working capital items. The cash flow is expected to improve in the end of the

year, the same as last year.

The demand for semiconductor wafers has clearly picked up as of March, which predicts strong

development starting from the second quarter. The demand for sensor wafers, on the contrary,

will probably reach full speed a little later, that is, during the second half of the year. The

demand for sensor wafers has been restrained by high inventory levels and the increasing focus

of sensors on consumer electronics, exposed to economic fluctuations. In the period under

review, technology sales consisted largely of solar crystal sales.”

1,000 euro 1.1.-31.3.12 1.1.-31.3.11 1.1.-31.12.11 1.1.-31.12.10

Net sales 18,902 22,055 83,186 80,907

Operating profit

before depreciation

(EBITDA)

3,052

4,425

18,069

17,102

Operating profit 1,535 2,828 11,817 10,421

% of net sales 8.1 12.8 14.2 12.9

Profit for the period 712 2,724 10,235 9,952

Basic earnings

per share, euro

0.04

0.16

0.61

0.60

Net cash flow from

operating activities

-996

-1,337

11,691

16,594

Net interest-

bearing liabilities

-6,071

-12,379

-10,257

-18,047

Equity ratio, % 79.2 78.9 78.9 76.6

Average number

of personnel

during the period

351

347

363

345

3(17)

Customer industries sensor, semiconductor, and solar cell industries

Sensor industry

In 2012, the sale value of sensor industry is estimated to grow 11-15 percent compared to the

sale value of 2011 (8.6-10.2 billion US dollars). One of the fastest growing sectors is MEMS

products for consumer applications such as microphones and gyroscopes. In the next few years

picoprojectors are estimated to be a significant growth area in consumer applications. (IHS

iSuppli, IC Insights, Yole) Nowadays, silicon-on-insulator (SOI) technology is widely used in the

manufacture of these next generation products, and the share of SOI technology is estimated to

continue its growth. Okmetic is amongst the pioneering suppliers who provide products and

services based on SOI technology to the sensor industry.

Semiconductor industry

The US dollar based sales of the semiconductor industry have started to recover during the first

quarter of the year. The estimates for the sale development in 2012 have improved and they

settle now at a level of 3-7 percent of annual growth. (IHS iSuppli, Gartner, IC Insights, VLSI

Research)

The growth in demand that started in the first quarter of 2012 is expected to accelerate in the

second half of the year (IDC). The demand for semiconductors is boosted by both strongly

increasing applications, such as tablet computers, and the uplift of developing markets (Gartner).

In the long run, the growth rate of semiconductor demand is estimated to remain at a yearly

level of 5-9 percent (IDC, IC Insights). The growth rate of discrete and power semiconductors is

estimated to slightly exceed the semiconductor market average (IC Insights, IHS iSuppli, Yole).

Solar cell industry

The almost 10-year-long very strong 40-50 percent annual growth of new solar energy based

(Photovoltaic) power plants is moderating. On average, annual growth of 20-30 percent is

estimated for the near future. (IHS iSuppli) The use of solar energy for electricity production is

expanding to more and more countries as the costs go down. Already over 20 countries are

estimated to build more than 100MW of capacity during 2012. (IMS Research)

In the short run, the changes in feed-in tariffs in Germany and Italy create uncertainty in the

market. Significant overproduction and structural change throughout the industry’s supply chain

are predicted to continue during 2012.

Silicon wafer market

According to the statistics published in February 2012 by SMG, the group of silicon wafer

suppliers in SEMI, the surface area of wafer shipments in the whole silicon wafer industry in

2011 decreased by three percent compared to 2010 area shipments. The transfer of the market

to bigger wafer sizes along with the technological development was stronger than average.

Compared to the previous year, a growth of three percent is estimated for 2012.

4(17)

Okmetic’s central customer areas in the silicon wafer market

In line with its strategy, Okmetic seeks for special areas of the entire silicon wafer market that

have greater growth rates than the market average and in which the company has special

expertise. Okmetic supplies primarily 150mm and 200mm wafers. The sensor/MEMS industry is

Okmetic’s central growth area. The MEMS market grows as portable consumer products,

automotive electronics, and industrial process control increase.

In the semiconductor market, Okmetic’s growth areas include discrete and power

semiconductors. The growth areas of these markets are i.a. components used in the production

of renewable energy, increasing automotive electronics, portable consumer products, as well as

different solutions related to power supply and efficiency improvement.

In January-March, Okmetic’s net sales amounted to 18.9 (22.1) million euro. There was a

decrease of 14.3 percent (growth 33.5%) for the comparison period mainly due to the prevailing

market trend. Okmetic’s market share grew in the product groups which are important to the

company, and sales improved clearly towards the end of the first quarter because of the

strengthened economic situation.

Sales per customer area

1.1.-31.3.12 1.1.-31.3.11 1.1.-31.12.11 1.1.-31.12.10

Sensors 46% 45% 46% 43%

Semiconductors 34% 33% 35% 42%

Technology 20% 22% 19% 15%

In January-March, the value of sensor wafer shipments was 14.0 percent lower than in the

corresponding period last year. Sensor wafer sales were weighed down by the customers’

bloated inventory levels in the beginning of the year. The demand for sensor wafers is expected

to pick up in the second half of the year.

The downward trend in the semiconductor industry saw a clear change at the end of the first

quarter which contributed positively to the semiconductor wafer sales. Due to the low demand

in January-February, the shipment value of the first quarter was 10.3 percent lower than in the

corresponding period last year.

In January-March, technology sales consisted mainly of solar crystal sales.

Sales per market area

1.1.-31.3.12 1.1.-31.3.11 1.1.-31.12.11 1.1.-31.12.10

North America 36% 37% 37% 43%

Europe 26% 31% 30% 25%

Asia 38% 32% 33% 32%

In the first quarter, the sales were strongest in Asia and North America. The relative proportion

of Asia of the net sales grew during the period under review.

5(17)

January-March

In January-March, Okmetic’s operating profit was 1.5 (2.8) million euro. The operating profit

accounted for 8.1 (12.8) percent of net sales. Profit for the period amounted to 0.7 (2.7) million

euro. Basic earnings per share was 0.04 (0.16) euro. Diluted earnings per share was 0.04

(0.16).

The company’s financial situation is good. In January-March, net cash flow from operations

amounted to -1.0 (-1.3) million euro. The cash flow from operations was weakened by 3.9 (6.0)

million euro due to changes in working capital available to business operations.

On 31 March 2012, the company’s liabilities amounted to 1.0 (1.0) million euro.

At the end of the period, cash and cash equivalents amounted to 7.2 (10.4) million euro. On 31

March 2012, the company’s cash and cash equivalents exceeded the interest-bearing liabilities

by 6.2 million euro (on 31 March 2011, cash and cash equivalents were 12.4 million euro higher

than interest-bearing liabilities). The group has ensured the sufficiency of cash funds by

increasing the committed credit facility of 3.0 million euro to 6.0 million euro. The credit facility

was undrawn on 31 March 2012.

Return on equity amounted to 4.6 (18.3) percent. The company’s equity ratio was 79.2 (78.9)

percent. Equity per share was 3.69 (3.63) euro.

In January-March, Okmetic’s capital expenditure amounted to 2.6 (4.8) million euro.

The investments concerned mainly the board’s decision in April 2011 to increase SOI wafer

production capacity by extending the Vantaa plant. The around 30 million euro investment

programme, to be implemented in 2011-2013, includes the plant extension and different kinds

of production equipment. Building of the plant extension started in August 2011.

In January-March, the company expensed 0.5 (0.6) million euro in product development

projects. Product development costs accounted for 2.8 (2.7) percent of net sales. The product

development costs have not been capitalised. Product development has been allocated to SOI

wafers and high and low resistivity wafers.

On average, Okmetic employed 351 (347) people in January-March. At the end of the period,

311 of the company’s employees worked in Finland, 36 in the US, four in Japan, and one in

Hong Kong.

6(17)

Okmetic Oyj’s annual general meeting, which was held on 12 April 2012, adopted the annual

accounts and the consolidated annual accounts for 2011 and discharged the company’s

management from liability. It was decided that a dividend of 0.28 euro per share would be

distributed for 2011. The dividend was paid on Tuesday 24 April 2012. The annual general

meeting decided also, in accordance with the proposal of the board of directors, to authorise the

board of directors to decide upon its discretion on the payment of an additional dividend, should

the company’s financial situation permit this. The additional dividend, including all possible

separate decisions on dividend payment, may amount up to a maximum of 0.40 euro per share

and 15,000,000 euro in total. Moreover, the general meeting approved the proposal of the

board of directors to authorise the board of directors to decide on the repurchase and/or the

acceptance as pledge of the company’s own shares as well as on the issuance of shares, the

transfer of the company’s own shares, and the issuance of special rights entitling to shares.

It was decided that there would be five members on the company’s board of directors. Mr. Henri

Österlund, Mr. Tapani Järvinen, Mr. Hannu Martola, and Ms. Mervi Paulasto-Kröckel were re-

elected as members of the board of directors until the end of the next annual general meeting,

and Mr. Mikko Puolakka was elected as a new member. The board of directors elected Henri

Österlund as its chairman and Tapani Järvinen as its vice chairman in its organisation meeting

held immediately after the annual general meeting.

Authorised Public Accountant PricewaterhouseCoopers Oy was elected as auditor, with APA

Mikko Nieminen having the principal responsibility.

Authorisations given to the board of directors and other decisions of the annual general meeting

have been notified in a stock exchange release published on 12 April 2012.

There have been no essential changes in the company’s near future business risks and

uncertainties. Okmetic's business operations are exposed to risks which may arise from the

company's operations or changes in the business environment.

Okmetic’s silicon wafer sales are targeted at the sensor and semiconductor producers in the

electronics industry. The demand for semiconductor wafers is sensitive to economic fluctuations

and changes in the market situation can be sudden and dramatic. The demand for sensor wafers

is more stable. The proliferation of sensors in consumer electronics applications may, however,

increase the susceptibility of this market too to economic fluctuations. Technology sales

comprise mainly crystal sales, which is predominantly affected by the economic situation of the

solar cell industry.

Okmetic’s share of the global silicon wafer market is around one percent and the market prices

have a notable effect on the price development of Okmetic’s products. The company only has

considerable pricing power with its own special products. The pricing of other wafers is mainly

based on global market price.

Okmetic operates globally, and therefore the company's business operations are affected by

risks due to currency fluctuations, consisting of the cash flows of purchases and sales. A

significant part of sales are conducted in US dollars. The Japanese yen is another notable

trading currency. Despite hedging, the company remains exposed to exchange rate fluctuations.

7(17)

Substantial volumes of electricity are used in Okmetic’s production. Despite hedging, the

company is exposed to fluctuations in the price of electricity.

The company risks and uncertainty factors are dealt more profoundly in the company’s annual

report of 2011.

On 31 March 2012, Okmetic Oyj’s paid-up share capital, as entered in the Finnish Trade

Register, was 11,821,250.00 euro. The number of shares was 17,287,500. The shares have no

nominal value attached. Each share entitles its holder to one vote at general meetings. The

company has one class of shares. The company’s shares are included in the Finnish book-entry

securities system.

A total of 1.1 (3.6) million shares were traded between 1 January and 31 March 2012,

representing 6.6 (20.8) percent of the weighted average of share total of 17.3 (17.3) million

during the period. The lowest quotation during the period was 4.98 (5.30) euro, and the highest

6.01 (6.65) euro, with the average being 5.63 (5.90) euro. The closing quotation for the period

was 5.82 (6.55) euro. At the end of the period, the market capitalisation amounted to 100.6

(113.2) million euro.

On 8 February 2012, Okmetic Oyj’s board of directors announced of its decision to transfer a

total of 56,033 own shares held by the company as a part of the company’s share-based

incentive scheme for the executive management group, of which the company has given a stock

exchange release on 11 February 2010. All the shares were issued to the members of the

executive management group in deviation from the shareholders’ pre-emptive rights (directed

share issue).

The rewards of the share reward programme were paid on one hand in Okmetic shares and on

the other hand in a monetary amount covering taxes. The directed share issue without payment

was executed in full as there was no consideration related to the issue.

At the end of the reporting period Okmetic held 241,543 own shares, which is approximately

1.4 percent of Okmetic’s all shares and votes.

The company Kiinteistö Oy Piitalot which was part of Okmetic group has merged with Okmetic

Oyj on 1 January 2012. Its assets and liabilities were transferred to Okmetic Oyj.

The Helsinki Court of Appeal gave a verdict in January in which it decided not to change the

acquittal for President Kai Seikku rendered by the Helsinki District Court on 20 December 2010

and dismissed the prosecutor’s claims on negligent abuse of insider information. The Helsinki

Court of Appeal’s verdict has entered into legal force as the prosecutor did not request for leave

to appeal from the next instance. The charge was related to Seikku’s actions while he was still

working for his previous employer HKScan Oyj.

8(17)

These interim financial statements have been prepared in accordance with IAS 34, Interim

Financial Reporting.

In preparing these interim financial statements, Okmetic has followed the same accounting

policies as in the financial statements for 2011 except for the effect of changes required by the

adoption of the following new or revised standards and interpretations as of 1 January 2012:

-IFRS 7 (amendment), Financial instruments: Disclosures – Derecognition.

-IAS 12 (amendment), Income Taxes – Deferred Tax.

The adoption of the aforementioned standards and interpretations has not had an effect on the

figures presented from the reporting period.

1,000 euro 1 Jan-31 Mar,

2012

1 Jan-31 Mar,

2011

1 Jan-31 Dec,

2011

Net sales 18,902 22,055 83,186

Cost of sales -14,851 -15,939 -61,876

Gross profit 4,051 6,116 21,310

Other income and expenses -2,515 -3,288 -9,493

Operating profit 1,535 2,828 11,817

Financial income and expenses -307 -532 -479

Profit before tax 1,229 2,296 11,339

Income tax -517 428 -1,104

Profit for the period 712 2,724 10,235

Other comprehensive income:

Cash flow hedges 127 - -177

Translation differences -106 -203 808

Other comprehensive income for

the period, net of tax

21

-203

631

Total comprehensive

income for the period

733

2,521

10,866

Profit for the period

attributable to:

Equity holders of the parent

company

712

2,724

10,235

Total comprehensive

income attributable to:

9(17)

Equity holders of the parent

company

733

2,521

10,866

Basic earnings per share, euro 0.04 0.16 0.61

Diluted earnings per share, euro 0.04 0.16 0.59

1,000 euro 31 Mar, 2012 31 Mar, 2011 31 Dec, 2011

Assets

Non-current assets

Intangible assets 83 - -

Property, plant and equipment

35,847

32,065

34,887

Other receivables 3,696 4,251 3,255

Total non-current assets

39,626

36,316

38,142

Current assets

Inventories 14,963 10,319 13,114

Receivables 16,933 17,461 15,374

Financial assets at fair value

through profit or loss

-

3,013

-

Cash and cash equivalents 7,154 10,366 11,257

Total current assets 39,049 41,158 39,745

Total assets 78,675 77,475 77,887

Equity and liabilities

Equity

Equity attributable

to equity holders of

the parent company

Share capital 11,821 11,821 11,821

Other equity 49,914 49,199 49,151

Total equity 61,735 61,021 60,973

Liabilities

Non-current liabilities 3,272 1,526 2,968

Current liabilities 13,669 14,927 13,946

Total liabilities 16,940 16,454 16,914

Total equity and liabilities 78,675 77,475 77,887

10(17)

1,000 euro 1 Jan-31 Mar,

2012

1 Jan-31 Mar,

2011

1 Jan-31 Dec,

2011

Cash flows from operating activities:

Profit before tax 1,229 2,296 11,339

Adjustments 2,192 2,735 7,575

Change in working capital -3,878 -5,950 -6,782

Financial items 11 -419 -401

Tax paid -520 - -39

Net cash from operating activities -966 -1,337 11,691

Cash flows from investing activities:

Purchases of property, plant and

equipment

-2,624

-3,908

-11,319

Investments in fixed income funds - 2,003 5,016

Net cash used in investing activities -2,624 -1,905 -6,302

Cash flows from financing activities:

Repayments of long-term borrowings - - -

Payments of finance lease liabilities - - -

Share issue - - -

Repurchase of own shares - - -1,147

Dividends paid -201 - -7,331

Net cash used in financing activities -201 - -8,478

Increase (+) / decrease (-)in cash

and cash equivalents

-3,791

-3,243

-3,089

Exchange rate changes -313 -434 304

Cash and cash equivalents at the

beginning of the period

11,257

14,043

14,043

Cash and cash equivalents at the end of

the period

7,154

10,366

11,257

11(17)

Equity attributable to equity holders of parent company

1,000 euro Share

capital

Share

premium

Reserve

for invested

unrestricted

equity

Other

reserves

1)

Retained

earnings

Total

Balance at

31 Dec, 2011

11,821

20,045

1,200

1,670

26,238

60,973

Profit for the

period

712

712

Other com-

prehensive

income, net

of tax:

Cash flow

hedges

127

127

Translation

differences

-106

-106

Total com-

prehensive

income for

the period

21

712

733

Share-based

payments

29

29

Balance at

31 Mar, 2012

11,821

20,045

1,200

1,691

26,977

61,735

Balance at

31 Dec, 2010

11,821

20,045

1,200

1,039

24,137

58,242

Profit for

the period

2,724

2,724

Other com-

prehensive

income, net

of tax:

Translation

differences

-203

-203

Total com-

prehensive

income for

the period

-203

2,724

2,521

Share-based

payments

258

258

Balance at

31 Mar, 2011

11,821

20,045

1,200

836

27,118

61,021

1)”Other reserves” contains hedge reserve and translation differences.

12(17)

1,000 euro

1 Jan-31 Mar,

2012

1 Jan-31 Mar,

2011

1 Jan-31 Dec,

2011

Carrying amount at the beginning

of the period

34,887

29,069

29,069

Additions 2,592 4,837 11,992

Disposals - - -

Depreciation 1,512 -1,597 -6,252

Exchange differences -120 -245 78

Carrying amount at the end of

the period

35,847

32,065

34,887

1,000 euro 31 Mar,

2012

31 Mar,

2011

31 Dec,

2011

Loans, secured with

collaterals

1,000

1,000

1,000

Collaterals 8,073 8,073 8,073

Off-balance sheet

lease commitments

435

206

426

Capital commitments 6,199 4,226 5,424

Nominal values of

derivative contracts

Currency options, call - 9,699 652

Currency options, put - 5,146 652

Currency forward agreements 154 - 154

Electricity derivatives 2,958 1,703 2,173

Fair values of

derivative contracts

Currency options, call - 226 0

Currency options, put - -9 -81

Currency forward agreements 5 - 1

Electricity derivatives -309 -210 -330

The contract price of the derivatives has been used as the nominal value of the underlying asset.

13(17)

1,000 euro 1 Jan-31 Mar,

2012

1 Jan-31 Mar,

2011

1 Jan-31 Dec,

2011

Net sales 18,902 22,055 83,186

Change in net sales compared to the

previous year’s period, %

-14.3

33.5

2.8

Export and foreign operations share

of net sales, %

95.1

94.6

94.4

Operating profit before

depreciation (EBITDA)

3,052

4,425

18,069

% of net sales 16.1 20.1 21.7

Operating profit 1,535 2,828 11,817

% of net sales 8.1 12.8 14.2

Profit before tax 1,229 2,296 11,339

% of net sales 6.5 10.4 13.6

Return on equity, % 4.6 18.3 17.2

Return on investment, % 7.9 15.1 18.7

Non-interest-bearing liabilities 15,857 15,454 15,914

Net interest-bearing liabilities -6,071 -12,379 -10,257

Net gearing ratio, % -9.8 -20.3 -16.8

Equity ratio, % 79.2 78.9 78.9

Capital expenditure 2,592 4,837 11,992

% of net sales 13.7 21.9 14.4

Depreciation 1,517 1,597 6,252

Research and development

expenditure

535

595

2,382

% of net sales 2.8 2.7 2.9

Average number of personnel during

the period

351

347

363

Personnel at the

end of the period

352

351

350

Euro 31 Mar, 2012 31 Mar, 2011 31 Dec, 2011

Basic earnings per share 0.04 0.16 0.61

Diluted earnings per share 0.04 0.16 0.59

Equity per share 3.69 3.63 3.68

Dividend per share - - 0.28

Dividends/earnings, % - - 45.8

Effective dividend yield, % - - 5.7

Price/earnings(P/E) - - 8.0

Share performance (1.1.-)

Average trading price 5.63 5.90 5.48

Lowest trading price 4.98 5.30 3.50

14(17)

Highest trading price

6.01

6.65

6.65

Trading price at the

end of the period

5.82

6.55

4.92

Market capitalization at the end of

the period, 1,000 euro

100,613

113,233

85,055

Trading volume (1 Jan-)

Trading volume, transactions, 1,000

pcs

1,141

3,601

10,907

In relation to weighted average

number of shares, %

6.6

20.8

63.1

Trading volume, 1,000 euro 6,422 21,242 59,650

The weighted average number of

shares during the period under review

adjusted by the share

issue, 1,000 pcs

17,288

17,288

17,288

The number of shares at the end of

the period adjusted by the share

issue, 1,000 pcs

17,288

17,288

17,288

When calculating earnings per share (EPS) and equity, Okmetic’s own shares in its possession

and Okmetic’s shares owned by Okmetic Management Oy are deducted from the amount of

shares.

1,000 euro 10-12/

2012

7-9/

2012

4-6/

2012

1-3/

2012

Net sales 18,902

Compared to previous quarter, % 4.2

Compared to corresponding

period last year, %

-14.3

Operating profit 1,535

% of net sales 8.1

Profit before tax 1,229

% of net sales 6.5

Net cash flow generated from:

Operating activities

-966

Investing activities -2,624

Financing activities -201

Increase/decrease in cash and cash

equivalents

-3,791

Personnel at the end of the period 352

15(17)

1,000 euro 10-12/

2011

7-9/

2011

4-6/

2011

1-3/

2011

Net sales 18,134 21,250 21,747 22,055

Compared to previous

quarter, %

-14.7

-2.3

-1.4

-4.4

Compared to corresponding

period last year, %

-21.4

-1.7

10.5

33.5

Operating profit 2,338 4,045 2,606 2,828

% of net sales 12.9 19.0 12.0 12.8

Profit before tax 2,439 4,117 2,487 2,296

% of net sales 13.4 19.4 11.4 10.4

Net cash flow generated from:

Operating activities

5,431

2,094

5,503

-1,337

Investing activities -4,332 -1,100 1,035 -1,905

Financing activities -2,771 -664 -5,043 -

Increase/decrease in cash and cash

equivalents

-1,672

330

1,495

-3,243

Personnel at the end of the period 350 350 389 351

Shares, pcs Share, %

Ilmarinen Mutual Pension Insurance Company 1,666,601 9.6

Mandatum Life Insurance Company Limited 810,500 4.7

The State Pension Fund 600,000 3.5

Varma Mutual Pension Insurance Company 477,175 2.8

Veritas Pension Insurance Company Ltd. 465,000 2.7

Okmetic Management oy 400,000 2.3

Etra-Invest Oy Ab 400,000 2.3

Nordea Nordic Small Cap Fund 370,660 2.1

Okmetic Oyj 241,543 1.4

Sijoitusrahasto Taaleritehdas Arvo Markka Osake 225,100 1.3

Kaleva Mutual Insurance Company 212,700 1.2

Aktia Secura Fund 201,182 1.2

Oy Ingman Finance Ab 200,051 1.2

Sijoitusrahasto Aktia Capital 140,387 0.8

EQ Pikkujättiläiset / EQ Rahastoyhtiö 140,000 0.8

Kiilholma Antti Tapio 92,248 0.5

Stenhäll Turo 75,000 0.4

Virtanen Yhtiöt Oy 70,000 0.4

Sr Eq Technology 60,000 0.4

Sr Arvo Finland Value 56,611 0.3

Foreign investors and nominee accounts held by

custodian banks

3,141,131

18.2

Others 7,241,611 41.9

Total 17,287,500 100.0

16(17)

Operating profit before

depreciation (EBITDA)

= Operating profit + depreciation

Return on equity (ROE), % = Profit/loss for the period x 100

Equity(Average for the period)

Return on investment (ROI), % = (Profit/loss before tax + interest and other financial

expenses) x 100

Balance sheet total – non-interest bearing liabilities(average

for the period)

Equity ratio, % = Equity x 100

Balance sheet total – advances received

Net interest-bearing liabilities = Interest-bearing liabilities – cash and cash equivalents

Net gearing ratio, % = (Interest-bearing liabilities – cash and cash equivalents) x

100

Equity

Earnings per share = Profit/loss for the period attributable to equity holders of

the parent company

Adjusted weighted average number of shares in issue

during the period

Equity per share = Equity attributable to equity holders of the parent company

Adjusted number of shares at the end of the period

Dividend per share = Dividend for the period

Adjusted number of shares at the end of the period

Effective dividend yield, % = Dividend per share x 100

Trading price at the end of the period

Price/earnings ratio (P/E) = Last adjusted trading price at the end of the period

Earnings per share

Average trading price = Total traded amount in euro

Adjusted number of shares traded during the period

Market capitalisation at the end

of the period

= Number of shares at the end of the period x trading price at

the end of the period

Trading volume = Number of shares traded during the period

Weighted average number of shares during the period

17(17)

All figures of the financial tables are rounded, and consequently the sum of individual figures can

deviate from the presented sum figure.

The future estimates and forecasts in this interim report are based on company management’s

current knowledge. Actual events and results may differ from the estimates presented here.

A press conference for the media and analysts will be held on Friday, 27 April 2012 at 1.00

p.m. at Helsinki World Trade Center, Aleksanterinkatu 17, second floor, Helsinki. In the

conference, Okmetic’s President Kai Seikku will present the group’s development in January-

March 2012 and prospects for 2012.

We ask participants to kindly give advance notice of their attendance by email to

communications@okmetic.com or by telephone to +358 9 5028 0406/Marika Mäntymaa.

Board of directors

For further information, please contact:

President Kai Seikku, Okmetic Oyj,

tel. +358 400 200 288, email: kai.seikku@okmetic.com

Senior Vice President, Finance, IT, and Communications

Juha Jaatinen, Okmetic Oyj, tel. +358 9 5028 0286,

email: juha.jaatinen@okmetic.com

Distribution:

NASDAQ OMX Helsinki

Principal media

www.okmetic.com

Take it higher

Okmetic is a technology company which supplies tailor-made silicon wafers for sensor and

semiconductor industries and sells its technological expertise to the solar cell industry. Okmetic

provides its customers with solutions that boost their competitiveness and profitability.

Okmetic’s silicon wafers are part of a further processing chain that produces end products that

improve human interaction and quality of life. Okmetic’s products are based on high-tech

expertise that generates added value for customers, innovative product development and an

extremely efficient production process.

Okmetic has a global customer base and sales network, production plants in Finland and the US

and contract manufacturers in Japan and China. Okmetic’s shares are listed on NASDAQ OMX

Helsinki under the code OKM1V. For more information on the company, please visit our website

at www.okmetic.com.